InnoCan Pharma Corporation
The Corporation's business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) research, development, marketing, distribution and sales of InnoCan-branded OTC pharmaceutical products; (ii) research and development of non-pharmaceutical products for third parties in exchange for fees and/or royalties; and (iii) research and development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales.
InnoCan Pharma Corporation (INNO)
le 24 septembre/September 2019
The common shares of InnoCan Pharma Corporation have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the trading date.